192 related articles for article (PubMed ID: 10527965)
1. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation.
Hoomans EH; Andersen AN; Loft A; Leerentveld RA; van Kamp AA; Zech H
Hum Reprod; 1999 Oct; 14(10):2442-7. PubMed ID: 10527965
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
Frydman R; Howles CM; Truong F
Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
[TBL] [Abstract][Full Text] [Related]
3. Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP).
Lenton E; Soltan A; Hewitt J; Thomson A; Davies W; Ashraf N; Sharma V; Jenner L; Ledger W; McVeigh E
Hum Reprod; 2000 May; 15(5):1021-7. PubMed ID: 10783345
[TBL] [Abstract][Full Text] [Related]
4. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI.
Hoomans EH; Mulder BB;
J Assist Reprod Genet; 2002 Oct; 19(10):470-6. PubMed ID: 12416651
[TBL] [Abstract][Full Text] [Related]
5. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.
Out HJ; Lindenberg S; Mikkelsen AL; Eldar-Geva T; Healy DL; Leader A; Rodriguez-Escudero FJ; Garcia-Velasco JA; Pellicer A
Hum Reprod; 1999 Mar; 14(3):622-7. PubMed ID: 10221686
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.
Bergh C; Howles CM; Borg K; Hamberger L; Josefsson B; Nilsson L; Wikland M
Hum Reprod; 1997 Oct; 12(10):2133-9. PubMed ID: 9402268
[TBL] [Abstract][Full Text] [Related]
7. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group.
Coelingh Bennink HJ; Fauser BC; Out HJ
Fertil Steril; 1998 Jan; 69(1):19-25. PubMed ID: 9457926
[TBL] [Abstract][Full Text] [Related]
8. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
[TBL] [Abstract][Full Text] [Related]
10. Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group.
Schats R; Sutter PD; Bassil S; Kremer JA; Tournaye H; Donnez J
Hum Reprod; 2000 Aug; 15(8):1691-7. PubMed ID: 10920087
[TBL] [Abstract][Full Text] [Related]
11. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
[TBL] [Abstract][Full Text] [Related]
12. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation.
Out HJ; Braat DD; Lintsen BM; Gurgan T; Bukulmez O; Gökmen O; Keles G; Caballero P; González JM; Fábregues F; Balasch J; Roulier R
Hum Reprod; 2000 Jan; 15(1):29-35. PubMed ID: 10611184
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study.
Tulppala M; Aho M; Tuuri T; Vilska S; Foudila T; Hakala-Ala-Pietilä T; Moilanen J; Bützow T; Kaukoranta S; Söderström-Anttila V; Siegberg R; Suikkari AM; Hovatta O
Hum Reprod; 1999 Nov; 14(11):2709-15. PubMed ID: 10548606
[TBL] [Abstract][Full Text] [Related]
14. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles.
Daya S; Gunby J
Cochrane Database Syst Rev; 2000; (4):CD002810. PubMed ID: 11034767
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.
Out HJ; Mannaerts BM; Driessen SG; Bennink HJ
Hum Reprod; 1995 Oct; 10(10):2534-40. PubMed ID: 8567765
[TBL] [Abstract][Full Text] [Related]
16. WITHDRAWN: Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles.
Daya S; Gunby J
Cochrane Database Syst Rev; 2007 Jul; 2006(3):CD002810. PubMed ID: 17636708
[TBL] [Abstract][Full Text] [Related]
17. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
[TBL] [Abstract][Full Text] [Related]
18. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
19. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization.
Latin-American Puregon IVF Study Group
Fertil Steril; 2001 Nov; 76(5):950-6. PubMed ID: 11704116
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted Reproduction Techniques in the Management of Infertility in the Netherlands.
Fragoulakis V; Pescott CP; Smeenk JM; van Santbrink EJ; Oosterhuis GJ; Broekmans FJ; Maniadakis N
Appl Health Econ Health Policy; 2016 Dec; 14(6):719-727. PubMed ID: 27581117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
